Inhalation Sciences Presented FDA-Funded Study Results on DissolvIt® and the APRINHA Project at the DDL Conference

Inhalation Sciences AB presented FDA‑funded positive data at the Drug Delivery to the Lungs conference in Edinburgh showing its DissolvIt® in vitro dissolution module produces PK profiles capable of predicting clinical plasma concentrations, indicating utility for bioequivalence assessments of inhaled drugs; concurrently, APRINHA project PK data demonstrated the company’s PreciseInhale® platform can distinguish subtle formulation differences and identify lead candidates. Company executives said the findings support faster, lower‑resource inhaled‑drug R&D with reduced animal use and improved regulatory alignment. The APRINHA collaboration—developing five inhaled apramycin formulations for lower respiratory tract infections—highlights near‑term commercial and regulatory relevance for ISAB’s CRO services and platform technologies.

Analysis

Inhalation Sciences presented FDA-funded results at the Drug Delivery to the Lungs conference in Edinburgh showing its DissolvIt® in vitro dissolution module generates pharmacokinetic (PK) data capable of predicting clinical plasma concentration profiles; the company and Director of Projects Maria Malmlöf framed this as supportive for bioequivalence assessments and a tool to de-risk and accelerate development timelines. ISAB also presented APRINHA project PK data demonstrating its PreciseInhale® platform can distinguish subtle formulation characteristics and identify the most suitable candidates among five apramycin inhalation formulations targeting lower respiratory tract infections, with Chief Scientific Officer Per Gerde highlighting reduced animal and active-substance use. These findings strengthen ISAB’s CRO value proposition by potentially aligning its proprietary platforms with regulatory recommendations and client needs for predictive in vitro–in vivo translation, which could lead to commercial collaborations. Market signals are mildly positive (sentiment score 0.3; market impact 0.28), but material upside depends on formal regulatory acceptance, reproducibility across sponsors, peer-reviewed validation, and conversion of platform validation into contracted revenue.

Key Decisions for Investors

• Monitor ISAB for formal regulatory endorsements, peer-reviewed publications, or announced commercial partnerships before increasing exposure as these are the primary revenue catalysts
• Adopt a staged or limited position reflecting the binary regulatory adoption risk and scale up only after evidence of client contracts or regulatory citations
• Track APRINHA project milestones (candidate selection, PK-to-clinical transition) and any reproducibility data across molecules as triggers to reassess upside
• Maintain position size limits or hedges given modest near-term market impact (sentiment 0.3, market impact 0.28) and the long lead time from platform validation to CRO revenue